OBJECTIVE：To provide reference for choosing a more economical first-line treatment for advanced or recurrent squamous cell NSCLC and reducting patients ’cost burden. METHODS ：Based on a published high-quality phase Ⅲ randomized clinical controlled trial ，Markov model was established according to the disease development process. The disease development process of patients with squamous cell NSCLC was divided into non-progressive free survival state ，disease progress state and death state. The cost-effectiveness analysis of ND regimen containing nedaplatin and CD regimen containing cisplatin was carried out on the basis of the treatment cost data of our hospital. The uncertainty of the results was evaluated with single factor sensitivity analysis and probability sensitivity analysis. RESULTS ：According to the results of analysis Markov model ，the cost-effectiveness in ND regimen was 54 995.58 yuan/QALYs，in CD regimen was 50 274.36 yuan/QALYs，and incremental cost-effectiveness ratio was 86 327.27 yuan/QALYs，which was lower than the willing payment threshold （193 932.00 yuan/QALYs）. The results of single factor sensitivity analysis showed that non-progressive free survival of patients accepted two regimens had the greatest influence on the cost-effectiveness analysis results. The probability sensitivity analysis showed that with the increase of per capita GDP in China ， the probability of cost-effectiveness of ND regimen increased gradually. CONCLUSIONS ：Compared with CD regimen ，ND regimen is more cost-effective in the treatment of advanced or recurrent squamous cell NSCLC.